Oncology
Refine Search
Pharmaceutical
Eli Lilly saw its shares close down 2.3% at $358.66, after the US major announced financial guidance for 2023, which was viewed as slightly disappointing. 14 December 2022
Biotechnology
Shares in Moderna were up by nearly a quarter at lunchtime Tuesday. 13 December 2022
Biosimilars
Biosimilar medicines deliver access for patients suffering from serious and debilitating conditions such as cancer, auto immune diseases, and diabetes. 13 December 2022
Biotechnology
Troubled US biotech Clovis Oncology has officially filed for bankruptcy in Delaware, hit by a fall in its cancer drug sales and challenges in raising additional capital, and will also seek to sell its assets through a court supervised sales process. 13 December 2022
Biotechnology
German immuno-oncology company Affimed has sought to impress with data on its blood cancer candidates at the ongoing ASH (American Society of Hematology) meeting. 13 December 2022
Biotechnology
US biotech major Regeneron added to its offering at this year’s American Society of Hematology (ASH) meeting with data on linvoseltamab in multiple myeloma. 13 December 2022
Biotechnology
A second KRAS blocker has won US approval, opening further a market in oncology based on a target that was once thought undruggable. 13 December 2022
Pharmaceutical
Indian pharmaceutical companies are on an acquisition spree after a decade of caution and organic growth. And their main target appears to be cancer drugs. As patient numbers continue to rise, the country's Parliamentary panel has also called for free cancer treatment to middle-class households through a government-funded health insurance scheme, reports The Pharma Letter’s India correspondent. 13 December 2022
Biotechnology
With Imbruvica (ibrutinib) sales of nearly $10 billion recorded by Janssen and AbbVie combined in 2021, the blood cancer drug has already changed the standard of care for patients in certain settings. 12 December 2022
Biotechnology
Clinical-stage biopharmaceutical company Ambrx Biopharma’s shares skyrocketed a whopping 1,000% by close of trading on Friday as it announced encouraging results in the Phase II trial of breast cancer drug ARX788. 12 December 2022
Biotechnology
On December 9, the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab), from Genentech, a USA-based subsidiary of Swiss pharma giant Roche, for adult and pediatric patients two years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). 12 December 2022
Biotechnology
Among notable research news last week, Swiss pharma giant Novartis released positive Phase III data on its prostate cancer candidate Pluvicto. Also, oncology specialist Mirati Therapeutics last Monday reported an analysis of a Phase III trial with its sitravatinib that was mixed, but the firm intends to press on with the study. A day later, Mirati also published mid-stage results for its lung cancer candidate adagrasib. On the deal-making front, the USA’s Summit Therapeutics saw its shares jump almost 200% as it announced a licensing deal with China’s Akeso for the latter’s cancer candidate ivonescimab that could cost it as much as $5 billion. Also, Vertex entered into a licensing deal for rights to Entrada Therapeutics’ myotonic dystrophy program and its lead candidate ENTR-701. 11 December 2022
Biotechnology
Shares of US biotech firm Arcellx roared up almost 26% to $27.24 by mid-morning, on the revelation of lucrative collaboration for its lead late-stage product candidate, CART-ddBCMA. 9 December 2022
Biotechnology
UK biotech Autolus Therapeutics has announced that the pivotal Phase II FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult acute lymphoblastic leukemia (ALL) has met its primary endpoint at interim analysis. 9 December 2022
Biotechnology
Anglo-Swedish drugmaker AstraZeneca has shown that its progress in treating breast cancer goes well beyond Enhertu (trastuzumab deruxtecan), the HER2-directed antibody drug conjugate being developed with Daiichi Sankyo that is fast becoming a blockbuster. 9 December 2022
Biotechnology
Updated results for Enhertu (trastuzumab deruxtecan) for the treatment of patients with HER2 positive metastatic breast cancer from the DESTINY-Breast03 and DESTINY-Breast02 Phase III trials have been presented at the 2022 San Antonio Breast Cancer Symposium. 8 December 2022
Biotechnology
Biotech start-up Dantari has announced its exit from stealth mode with a $47 million Series A financing. 8 December 2022
Pharmaceutical
US clinical-stage oncology company Revolution Medicines saw its shares fall as much as 7% to $22.81 yesterday, after it announced that French pharma major Sanofi has pulled out their global SHP2 development and commercialization collaboration, which could have earned the American company more than $500 million. 8 December 2022
Biotechnology
Swedish biotech Oncopeptides saw its shares plunge 36% to 12.00 Swedish kronor yesterday, after it revealed that the US Food and Drug Administration (FDA) has requested a withdrawal of the US marketing authorization for its multiple myeloma drug Pepaxto (melphalan flufenamide). 8 December 2022
Biotechnology
Trodelvy (sacituzumab govitecan-hziy), an antibody-drug conjugate (ADC) developed by California’s Gilead Sciences, has performed well in a post hoc analysis of the Phase III TROPiCS-02 study. 7 December 2022
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze